You just read:

Morphotek Announces Initiation Of Phase 1 Study Of Next-Generation Farletuzumab Antibody-Drug Conjugate MORAb-202 In Solid Tumors With Folate Receptor Alpha Expression

News provided by

Morphotek, Inc.

Dec 04, 2017, 09:00 EST